Ignite Creation Date:
2025-12-26 @ 5:23 PM
Ignite Modification Date:
2026-03-06 @ 6:01 AM
Study NCT ID:
NCT01013506
Status:
WITHDRAWN
Last Update Posted:
2013-05-23
First Post:
2009-11-12
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Phase 2, Endocrine Therapy + OSI-906 With or Without Erlotinib for Hormone-sensitive Metastatic Breast Cancer
Sponsor:
Vanderbilt-Ingram Cancer Center
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Breast Cancer | View |